Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • emc易倍官网入口Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • emc易倍官网入口Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • emc易倍官网入口Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • emc易倍官网入口Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • emc易倍官网入口Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • emc易倍官网入口 Brazil
    • emc易倍官网入口 Canada
    • United States
    • emc易倍官网入口 Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • emc易倍官网入口 Ukraine
    • UK
    • emc易倍官网入口 Germany
    • France
    • Nordics
    • Greece
    • emc易倍官网入口 Italy
    • Netherlands
    • emc易倍官网入口 Spain
    • Poland
    • Russia
    • emc易倍官网入口 Czech Republic
    • Romania
    • Hungary
    • emc易倍官网入口 Slovakia
    • Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • emc易倍官网入口Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • emc易倍官网入口Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • emc易倍官网入口Meet the team
    • Clinical Trials
        < Back
      • emc易倍官网入口Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • emc易倍官网入口Sustainability
    • Sustainability
    • Environment
    • emc易倍官网入口Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • emc易倍官网入口Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories

emc易倍官网入口

Previous
Next

emc易倍官网入口

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-08-19-Ipsen-Voting-rights

emc易倍官网入口

- 12 January 2021 - 1 mins read

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-08-19-Ipsen-Voting-rights

emc易倍官网入口

Previous
Next
Related stories
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
emc易倍官网入口 See more stories

emc易倍官网入口

11 July 2024

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
09 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
09 July 2024

Ipsen – June 2024 – Monthly information relative to the...
08 July 2024

Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
02 July 2024

Ipsen expands collaboration and license agreement for development of Cabometyx?...
25 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
18 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
11 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
10 June 2024

Ipsen’s Iqirvo? receives U.S. FDA accelerated approval as a first-in-class...

IPN price

€163.80

 €0.10 (0.06%)

  • emc易倍官网入口Media Resources
  • Annual Report
  • emc易倍官网入口 Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • emc易倍官网入口Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-19 17:47:39